Back to Agenda
Session 2: Advancing RMP Effectiveness Through Evidence, Expectations, and Digital Innovation
Session Chair(s)
Helen Fiddes
Head of Patient Safety, UK and Ireland, Bristol-Myers Squibb, United Kingdom
Session Overview: This session will explore the practical application and evaluation of Risk Minimisation Measures (RMMs) within the UK environment, focusing on both regulatory expectations and real-world implementation. Speakers will discuss how ARMM effectiveness is assessed, what “good” looks like from an MHRA perspective, and common challenges in ensuring meaningful patient and HCP impact. The session will also highlight the future of educational materials, showcasing how digital solutions - from QR codes to app-based resources - can support more accessible, efficient, and modern risk minimisation strategies.
Speaker(s)
Robert Massouh, MPharm, RPh
Head of Safety (PV) Risk Management and Benefit/Risk Evaluation, GSK, United Kingdom
ARMMs Effectiveness Checks
Kathryn Ord
Expert Benefit Risk Evaluation Assessor, Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
What does the MHRA expect? Implementation of RMMs
Louise Okeeffe
Senior Safety Development Director, Roche Products Ltd., United Kingdom
Digitalization of Educational Materials: General Aspects and Case Example
Payal Gupta
Senior Patient Safety Partner & RMP-IC, Roche Products Ltd, United Kingdom
Digitalization of Educational Materials: General Aspects and Case Example
Have an account?